Omschrijving
The Symposium on New Drugs provides a forum for academic investigators, research and development personnel from the pharmaceutical industry and members of the Food and Drug Administration to discuss important clinical research issues. The Ninth Annual symposium on New Drugs addressed the problem of determining the risk versus benefit for use of three important classes of cardiovascular agents: thrombolytic, antiarrhythmic, and hypolipidemic agents. The use of thrombolytic agents has become one of the major advances in clinical intensive cardiologic care in the 1980s. While the lysis of clot(s) obstructing a major coronary artery should reverse or prevent the damage of acute myocardial ischemia and infarction, one must carefully consider the potential risks of such agents in regards to thei
Kenmerken
| Artikelnummer | 9200000042858194 |
|---|---|
| EAN | 9781461316053 |
| Categorie | Digital Reading |
| Productgroep | Boeken |
| Segment | Textual/Printed/Reference Materials |
| Prijs Nederland | € 148,99 |
| Prijs België | € 148,99 |
| Verzendkosten NL | Gratis |
| Verzendkosten BE | Gratis |
| Levertijd Nederland | Morgen in huis |
| Levertijd België | Morgen in huis |
| Verkoper | Partner |
Developments in Cardiovascular Medicine 100 - Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents bestellen bij snelkeus
Koop Developments in Cardiovascular Medicine 100 - Risk/Benefit Analysis for the Use and Approval of Thrombolytic, Antiarrhythmic, and Hypolipidemic Agents van Onbekend online in de categorie Digital Reading. Prijs € 148,99, levering in Nederland · Morgen in huis.